Clay Siegall, Life Science Washington via YouTube
February 10, 2022 01:59 PM ESTUpdated 05:09 PM
Pharma

Seagen's stock plunges af­ter re­veal­ing a dis­ap­point­ing out­look for one of its core can­cer drugs

Nicole DeFeudis

Editor

With sales up 38% last year com­pared to 2020, Seagen CEO Clay Sie­gall used the com­pa­ny’s Q4 call to high­light what he called an ex­cep­tion­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Pfiz­er hires ex-FDA deputy Pa­trizia Cavaz­zoni as chief med­ical of­fi­cer

Post-Hoc: Phar­ma CEOs' al­ter­na­tive re­al­i­ty with Trump

Pfiz­er wants in on Sum­mit’s goal to beat Keytru­da via ADC com­bos

FDA lifts hold on En­trada's Duchenne drug af­ter two years

Some FDA med­ical de­vice staff re­in­stat­ed just days af­ter re­ceiv­ing pink slips

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times